A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants

NCT05885451 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Graft-versus-Host Disease (cGVHD)

Interventions

DRUG: AMG 592
OTHER: Placebo

Sponsor

Amgen